lower
respiratori
tract
infect
lrti
common
littl
known
respons
biomark
inflamm
lung
therefor
primari
aim
compar
concentr
llactat
concentr
neutrophil
sputum
system
marker
infect
difficult
differenti
viral
bacteri
infect
basi
clinic
present
lrti
secondari
aim
evalu
land
dlactat
may
serv
marker
local
inflamm
repres
neutrophil
bacteria
respect
method
patient
acut
lrti
prospect
recruit
sputum
sampl
collect
analys
neutrophil
count
llactat
dlactat
data
pathogen
sputum
cultur
polymeras
chain
reaction
pcr
atyp
bacteria
viru
creactiv
protein
crp
blood
result
sputum
sampl
patient
median
interquartil
rang
iqr
sputum
neutrophil
granulocyt
count
cellsml
sputum
neutrophil
granulocyt
count
associ
sputum
llactat
p
crp
p
dlactat
p
strong
associ
sputum
dlactat
llactat
p
conclus
llactat
sputum
close
correl
sequestr
neutrophil
lung
llactat
marker
local
inflamm
lrti
potenti
biomark
clinic
manag
lrti
expector
sputum
dlactat
clinic
relev
lower
respiratori
tract
infect
lrti
common
respons
biomark
inflamm
lung
howev
far
fulli
understood
marker
inflamm
pulmonari
infect
studi
patient
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
cf
cfrelat
chronic
airway
inflamm
tissu
remodel
thought
caus
neutrophil
present
larg
number
airway
cf
patient
studi
sputum
cf
patient
pulmonari
exacerb
associ
sputum
neutrophil
count
sputum
lactat
howev
studi
differenti
two
isom
lactat
increas
marker
neutrophil
inflamm
sputum
found
associ
bacteri
infect
copd
exacerb
potenti
lead
increas
level
llactat
dlactat
lrti
differenti
viru
bacteria
base
clinic
present
lrti
difficult
hospit
set
caus
pathogen
detect
nearli
half
pneumonia
case
often
mix
pathogen
reduc
unnecessari
prescript
antibiot
viral
lrti
need
marker
differenti
viral
bacteri
infect
detect
fail
natur
lactat
exist
two
isoform
llactat
dlactat
produc
pyruv
isomericspecif
enzym
llactat
dehydrogenas
lldh
dlactat
dehydrogenas
dldh
llactat
produc
human
tissu
pyruv
anaerob
metabol
carbohydr
primari
form
lactat
human
dlactat
produc
lower
organ
equip
dldh
bacteria
dlactat
synthesi
possibl
mammal
via
methylglyox
pathway
pathway
gener
moder
amount
dlactat
bloodstream
blood
dlactat
level
healthi
human
often
undetect
appropri
laboratori
analysi
usual
low
contrast
littl
known
respons
lactat
isom
toward
bacteria
viru
site
infect
name
lung
studi
clinic
util
dlactat
indic
ongo
bacteri
infect
variou
compart
indic
dlactat
may
prove
use
supplement
assess
effect
antimicrobi
therapi
bacteri
infect
pleural
fluid
sensit
dlactat
indic
ongo
bacteri
infect
specif
therefor
secondari
aim
assess
util
sputum
dlactat
marker
pulmonari
bacteri
invas
marker
inflamm
pulmonari
infect
studi
patient
copd
cf
cfrelat
chronic
airway
inflamm
tissu
remodel
thought
caus
neutrophil
present
larg
number
airway
cf
patient
studi
sputum
cf
patient
pulmonari
exacerb
associ
sputum
neutrophil
count
sputum
lactat
howev
studi
differenti
two
isom
lactat
increas
marker
neutrophil
inflamm
sputum
found
associ
bacteri
infect
copd
exacerb
potenti
lead
increas
level
llactat
dlactat
altogeth
aim
assess
util
sputum
llactat
sputum
dlactat
marker
pulmonari
neutrophil
inflamm
bacteri
invas
lung
patient
admit
acut
lrti
studi
prospect
observ
studi
involv
patient
admit
emerg
ward
acut
infect
patient
enrol
prospect
soon
admiss
base
clinic
suspicion
pneumonia
caus
lrti
patient
new
purul
expector
particip
enrol
compli
criteria
communityacquir
pneumonia
admiss
xwould
avail
elig
patient
lrti
defin
work
diagnosi
base
clinic
judgement
involv
purul
expector
well
minimum
one
follow
cough
fever
chest
pain
avail
infiltr
xray
patient
year
old
abl
expector
could
enrol
particip
recruit
consecut
workday
monday
friday
either
stay
emerg
ward
transfer
depart
lung
infecti
diseas
univers
hospit
nordsjaelland
novemb
march
patient
abl
expector
will
particip
unlik
surviv
follow
h
exclud
studi
approv
region
scientif
ethic
committe
vek
accord
declar
helsinki
studi
subject
gave
written
inform
consent
inclus
studi
data
demographi
comorbid
obtain
questionnair
given
particip
day
inclus
day
paraclin
paramet
eg
blood
leucocyt
count
crp
obtain
medic
record
data
prior
antibiot
treatment
corticosteroid
use
obtain
questionnair
medic
record
research
sampl
priorit
secondarili
routin
sampl
microbiolog
assess
sputum
collect
admiss
enrol
repeat
particip
abl
produc
purul
expector
sampl
subsequ
day
sputum
sampl
dilut
homogen
phosphatebuff
salin
pb
ph
substrat
depart
panum
institut
denmark
store
analysi
sputum
alreadi
sent
routin
analysi
sampl
divid
two
aliquot
one
sent
routin
analysi
depart
clinic
microbiolog
herlev
univers
hospit
result
report
presenc
ident
pathogen
detect
sputum
respiratori
pathogen
identifi
cultur
use
biochem
method
andor
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
atyp
bacteria
mycoplasma
pneumonia
chlamydophila
pneumonia
chlamydophila
psittaci
legionella
pneumophila
identifi
use
realtim
pcr
respiratori
virus
identifi
use
pcr
eg
metapneumoviru
rhinoviru
influenza
influenza
b
parainfluenza
respiratori
syncyti
viru
rsv
concentr
neutrophil
sputum
shown
exact
number
determin
ad
dilut
sputum
trucount
tube
bd
becton
dickinson
addit
follow
mous
antihuman
monoclon
antibodi
bd
bioscienc
la
jolla
ca
usa
ad
sampl
peridinin
chlorophyl
proteinlabel
percp
fluorescein
isothiocyan
fitc
label
allophycocyanin
apc
label
sampl
incub
min
fixat
ml
fluorescenceactiv
cell
sorter
fac
lysi
solut
store
overnight
dark
analysi
flow
cytometri
use
facscanto
bd
bioscienc
equip
mv
argonion
laser
tune
nm
red
laseremit
diod
nm
excit
lightscatt
exponenti
amplifi
fluoresc
paramet
record
least
event
leucocyt
identifi
gate
polymorphonuclear
leukocyt
pmn
discrimin
gate
previous
describ
instrument
calibr
cs
bead
bd
bioscienc
franklin
lake
nj
usa
concentr
dlactat
sputum
measur
sampl
use
dlactat
colorimetr
assay
kit
sigmaaldrich
missouri
mo
usa
accord
manufactur
recommend
sampl
dilut
use
concentr
rang
mm
dlactat
exceed
frozen
sampl
dilut
sputum
thaw
transfer
microtitr
plate
dlactat
concentr
estim
addit
reaction
mix
dlactat
buffer
dlactat
enzym
mix
dlactat
substrat
min
dark
room
temperatur
wherebi
dlactat
quantit
optic
densiti
nm
measur
enzymelink
immunosorb
assay
elisa
plate
reader
thermo
scientif
multiskan
ex
thermo
fisher
scientif
inc
bioimag
denmark
dlactat
concentr
determin
interpol
valu
gener
standard
curv
concentr
llactat
sputum
measur
sampl
use
llactat
assay
kit
sigmaaldrich
accord
manufactur
recommend
sampl
dilut
use
concentr
rang
mm
llactat
exceed
frozen
sampl
dilut
sputum
thaw
transfer
microtit
plate
llactat
concentr
estim
addit
master
reaction
mix
lactat
assay
buffer
lactat
enzym
mix
lactat
probe
min
dark
room
temperatur
wherebi
llactat
quantit
optic
densiti
nm
measur
elisa
plate
reader
thermo
scientif
multiskan
ex
llactat
concentr
determin
interpol
valu
gener
standard
curv
normal
distribut
data
express
mean
standard
deviat
nonnorm
distribut
express
median
interquartil
rang
iqr
categor
variabl
express
number
percentag
continu
variabl
adher
normal
distribut
analys
nonparametr
statist
correl
analys
base
linear
regress
model
present
beta
b
coeffici
confid
interv
ci
regress
analys
perform
investig
associ
neutrophil
granulocyt
count
sputum
llactat
dlactat
use
multilevel
mix
model
adjust
cluster
individu
one
sputum
sampl
account
intraindividu
correl
posthoc
qq
plot
standard
residu
perform
verifi
assumpt
normal
distribut
data
outlier
identifi
plot
data
kept
final
model
outlier
alter
correl
report
data
shown
pvalu
consid
statist
signific
descript
statist
linear
regress
includ
qq
plot
perform
stata
statacorp
lp
colleg
station
tx
usa
graph
made
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
thirtytwo
particip
met
criteria
particip
studi
sixteen
femal
median
iqr
age
year
tabl
data
preexist
pulmonari
diseas
avail
particip
copd
eight
asthma
two
pulmonari
fibrosi
total
sputum
sampl
collect
particip
although
admit
emerg
ward
particip
clinic
stabl
mean
rang
respiratori
rate
per
minut
heart
rate
beat
per
minut
systol
blood
pressur
mmhg
peripher
oxygen
satur
temperatur
c
antibiot
treatment
initi
particip
research
sampl
collect
among
particip
data
corticosteroid
treatment
use
oral
prednisolon
use
inhal
corticosteroid
five
mix
use
neutrophil
count
assess
sputum
sampl
median
neutrophil
count
cellsml
iqr
level
measur
paramet
shown
tabl
measur
llactat
perform
sputum
sampl
median
fig
neutrophil
count
associ
level
dlactat
sputum
b
ci
p
fig
also
found
associ
sputum
llactat
sputum
dlactat
b
ci
p
fig
differ
level
blood
crp
particip
neg
sputum
cultur
compar
verifi
bacteria
b
ci
n
p
differ
level
blood
crp
particip
verifi
viral
lrti
compar
without
b
ci
n
p
measur
neutrophil
count
two
isoform
lactat
land
dlactat
sputum
patient
admit
acut
lrti
found
associ
sputum
neutrophil
count
llactat
dlactat
saw
includ
two
sampl
mix
bacteri
viral
aetiolog
includ
three
sputum
sampl
one
bacteri
pathogen
includ
two
sampl
mix
bacteri
viral
aetiolog
associ
llactat
dlactat
viral
infect
llactat
dlactat
bacteri
infect
differ
sputum
neutrophil
count
among
particip
without
verifi
pathogen
earlier
studi
sputum
neutrophil
count
copd
cf
patient
demonstr
augment
neutrophil
count
exacerb
decreas
baselin
valu
erad
infect
reason
believ
elev
sputum
neutrophil
count
acut
lrti
declin
treat
appropri
low
detect
rate
bacteria
clinic
laboratori
may
explain
see
associ
dlactat
bacteria
expect
bacteri
infect
neutrophil
granulocyt
recruit
bloodstream
focu
infect
pneumonia
expect
result
increas
neutrophil
count
lung
sputum
howev
inaccess
spontan
expector
sputum
noninflam
person
without
infect
prevent
inclus
sputum
sampl
healthi
person
appropri
control
find
neutrophil
count
lrti
sputum
unaffect
detect
viru
bacteria
line
copd
patient
exacerb
indic
strong
contribut
viral
infect
lung
inflamm
lrti
patient
earlier
studi
demonstr
lung
capabl
releas
lactat
metabol
glucos
although
net
balanc
lactat
close
zero
healthi
lung
human
neutrophil
metabol
lactat
produc
glycolysi
cleavag
ldh
diseas
state
acut
lung
injuri
net
product
pulmonari
lactat
increas
correl
sever
lung
injuri
lactat
product
thought
due
augment
cytokin
effect
pulmonari
inflammatori
cell
addit
viral
infect
human
cell
may
induc
warburg
effect
lead
product
llactat
elev
level
llactat
sputum
associ
sputum
llactat
sputum
neutrophil
count
strengthen
theori
llactat
metabolit
human
neutrophil
rais
level
llactat
may
indic
ongo
airway
inflamm
lrti
previou
studi
lactat
product
increas
acut
lung
injuri
differenti
two
isoform
land
dlactat
mammal
amount
lldh
exce
amount
dldh
far
therefor
llactat
primari
isoform
lactat
human
metabol
activ
bacteria
halt
immedi
earli
phase
antibiot
treatment
dlactat
shown
potenti
use
biomark
success
therapi
measur
dlactat
antibiot
treatment
variou
bodi
compart
promis
indic
decreas
bacteri
load
studi
dlactat
detect
sputum
could
demonstr
associ
sputum
neutrophil
count
sputum
dlactat
indic
dlactat
origin
neutrophil
instead
assum
studi
bacteria
may
sourc
dlactat
howev
assumpt
challeng
lack
associ
bacteria
dlactat
studi
specul
antibiot
treatment
may
confound
distribut
dlactat
sputum
sampl
reduc
bacteri
product
dlactat
viru
bacteria
detect
respect
sputum
sampl
patient
acut
lrti
studi
line
previou
studi
howev
detect
mix
bacterialvir
lrti
contrast
previou
studi
find
mix
infect
lack
detect
microb
may
prevent
use
bronchoalveolar
lavag
use
tool
diagnos
lrti
despit
antibiot
initi
particip
rate
posit
cultur
rel
high
studi
one
could
consid
antibiot
erad
sensit
bacteria
lead
less
divers
allow
overgrowth
bacteria
involv
infect
could
explain
associ
bacteri
infect
dlactat
studi
viral
infect
dlactat
alreadi
suggest
viru
may
disrupt
respiratori
mucos
epithelium
impair
immun
system
seen
influenza
often
superinfect
staphylococcu
aureu
support
strong
associ
sputum
dlactat
llactat
present
studi
dlactat
qualifi
good
marker
differenti
bacteri
viral
infect
llactat
seem
strongli
associ
sever
local
pulmonari
inflamm
research
sampl
done
first
encount
particip
alreadi
admit
initi
antibiot
sampl
prefer
done
directli
admiss
initi
antibiot
treatment
could
priorit
research
sampl
clinic
sampl
could
impair
detect
rate
unfortun
almost
fifth
sampl
microbiolog
contamin
lost
reduc
number
specimen
detect
sampl
prefer
done
initi
antibiot
treatment
cultur
common
pathogen
lrti
eg
streptococcu
pneumonia
difficult
initi
thu
like
cultur
sampl
infect
particip
contain
nonviabl
bacteria
could
identifi
clinic
laboratori
potenti
could
found
differ
pcr
use
cultur
expector
sampl
treat
antibiot
eg
penicillin
may
caus
opportunist
growth
mainli
gramneg
bacteria
eg
escherichia
coli
rare
lrti
pathogen
seen
studi
shown
llactat
sputum
associ
neutrophil
invas
lung
mix
bacterialvir
lrti
n
thirteen
posit
sputum
sampl
patient
acut
lrti
although
dlactat
sputum
marker
specif
interest
sinc
uniqu
bacteri
metabol
clinic
relev
current
studi
sputum
llactat
dlactat
associ
viral
lrti
bacteri
suggest
greater
inflammatori
respons
viral
mix
viralbacteri
bacteri
lrti
suggest
may
verifi
compar
bloodderiv
biomark
propos
discrimin
bacteri
viral
nonbacteri
lrti
procalcitonin
llactat
wide
avail
measur
laboratori
set
recommend
studi
focu
use
marker
repres
invas
leucocyt
lung
furthermor
llactat
evalu
marker
monitor
treatment
respons
directli
lung
may
sensit
system
marker
crp
final
patient
admit
lrti
often
stop
produc
sputum
earli
cours
infect
llactat
test
patient
intub
tracheostomi
routin
tracheal
suction
perform
studi
support
nordsjaelland
hospit
